As a world-leading service provider of antibody development and generation, Creative Biolabs is ready to provide a whole series of biomarker-specific in vitro diagnostic (IVD) antibody development services. A team of experienced scientists focused on antibody development are pleased to assist you in your project in a timely and cost-effective manner. Here, we introduce our IVD antibody development services targeting hsTnl marker.

Troponin I is a cardiac and skeletal muscle protein that belongs to troponin complex. Troponin complex is located in the thin filament of the striated muscle contractile apparatus and is composed of troponin I, troponin T and troponin C, each coded by an individual gene. Troponin I binds to actin in thin myofilaments and thus keeps the actin-tropomyosin complex in place. Troponins are primarily bound to the myofibrils, although, 2.8–4.1% of cardiac troponin I (cTnI) and 6–8% of cardiac troponin T (cTnT) are cytosolic. After ischaemic injury, cytosolic cTnT is quickly released, subsequently more prolonged myofibrillar troponin is released, leading to a biphasic release pattern. The release of cTnI is probably to be monophasic because it has a smaller cytosolic pool. It has indicated that determination of plasma concentration of cTnT can be used for the identification of cardiac muscle damage. Now, the determination of extremely low concentrations of circulating cardiac troponin is possible by highly sensitive assays.

IVD Antibodies for hsTnI Marker Figure 1. The schematic diagram of troponin complex which is composed of troponin I, troponin C and troponin T. Troponin I, a cardiac and skeletal muscle protein, is usually used as a marker in the diagnosis of heart attack. (Palpant, N. J. 2010)

hsTnI Marker in NSTEMI

Non-ST-segment elevation myocardial infarction (NSTEMI) is one type of the acute coronary syndrome (ACS), and other types of ACS are unstable angina (UA) and ST segment elevation myocardial infarction (STEMI). UA and NSTEMI mainly differ in whether the ischemia is serious enough to induce adequate myocardial damage to release enough quantities of a marker of myocardial injury. Modern troponin assays have been proven to promote the early diagnosis of NSTEMI at a high specificity. Researches have demonstrated that detections of hsTnI were highly available for the diagnosis of NSTEMI, especially in patient with preexisting cardiac diseases such as AF. hsTnI has become a novel and reliable marker for the early IVD of NSTEMI.

IVD Antibodies for hsTnI Marker Figure 2. NSTEMI, UA and STEMI make up the acute coronary syndromes (ACS). ACS is a syndrome on account of reduced blood flow in the coronary arteries so that part of the heart muscle is unable to function suitably or dies. (Sörensen, N. A. 2015)

hsTnI Marker in Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy (HCM) is a genetic situation with unclear left ventricular hypertrophy in the absence of LV chamber dilatation. It is a relatively usual situation carried an improved risk of arrhythmia and sudden cardiac death, even in those persons with clinically “silent” or unauthorized HCM. Lately, a study was demonstrated that hsTnI displayed a graded, positive association with detections of cardiac muscle mass in persons at risk of HCM. Also it has widely accepted that hsTnI assays will finally instead of cTnI assays as a diagnostic approach of cardiac disease, because they not only offer greater accuracy at the 99th percentile limits, but also measure lower levels of troponin “leak” with better sensitivity.

IVD Antibodies for hsTnI Marker Figure 3. Box plot of the natural log of hsTnI by HCM groups as stratified by standard echo criteria. HCM is very usual and can influence people of any age despite of men and women. It is a generally cause of sudden cardiac arrest in young people, comprising young athletes. (McGorrian, C. M. 2013)

IVD Antibody Development Services Targeting hsTnl Marker

IVD antibodies have been widely used for disease screening and therapeutic monitoring. As a research partner with years of experience in high-quality antibody development and production, Creative Biolabs offers one-stop solutions from antigen design to antibody pair screening. Besides, we also offer diagnostic immunoassay development services, including feasibility analysis, assay design, assay protocol establishment, assay optimization, and kit production. Our services can be tailor-designed to adapt to specific project specifications.

If you are interested in our services, please do not hesitate to contact us for more details.


  1. Palpant, N. J. (2010). “Pathogenic peptide deviations support a model of adaptive evolution of chordate cardiac performance by troponin mutations.” Physiological genomics 42(2), 287-299.
  2. McGorrian, C. M. (2013). “Use of a highly-sensitive cardiac troponin I assay in a screening population for hypertrophic cardiomyopathy: a case-referent study.” BMC cardiovascular disorders 13(1), 1.
  3. Sörensen, N. A. (2015). “High-sensitivity troponin and novel biomarkers for the early diagnosis of non-ST-segment elevation myocardial infarction in patients with atrial fibrillation.” European Heart Journal: Acute Cardiovascular Care, 2048872615611108.

For Research Use Only.

Online Inquiry

*E-mail Address:
*Service & Products Interested:
Project Description:

Contact Us




Follow us on:
Copyright © 2021 Creative Biolabs.
Inquiry Basket